Home›Trial›NCT06455202
🔬NCT06455202Phase 3ACTIVE NOT RECRUITING

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

Study Summary

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.

Conditions
Chronic Spontaneous Urticaria
Interventions / Drugs
barzolvolimabMatching placebo
View on ClinicalTrials.gov ↗
Sponsor
CLDX
Celldex Therapeutics
Immuno-Oncology
C50/100
Study Details
Enrollment976 participants
Primary Completion—
Lead SponsorCelldex Therapeutics
Data Retrieved2026-04-11 04:09:37.490176+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.